STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly has already established that its next-generation obesity drug can lead to highly rapid weight loss. Researchers disclosed new data Saturday that provide more details on the safety and tolerability of the closely watched therapy. Lilly previously said that in one late-stage study, called TRANSCEND-T2D-1, retatrutide helped people with diabetes lower blood sugar and lose a significant amount of weight, which is notable since those who have diabetes tend to lose less weight on treatment t...